Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
TAG Oil prepares for flow testing of its first unconventional oil well in Egypt (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Tharimmune Inc THAR

Healthcare Biotechnology
Tharimmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of therapeutic candidate for inflammatory and immunologic conditions. It has a transmucosal film product, TH104 in Phase I clinical development, two bispecific candidates and a Picobody candidate in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:THAR)

Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics

Accesswire 3 days ago

Tharimmune to Present at the Emerging Growth Conference on March 7, 2024

Accesswire March 5, 2024

Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate

Accesswire February 20, 2024

Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis

Accesswire February 5, 2024

Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update

Accesswire January 29, 2024

Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease Patients

Accesswire December 11, 2023

Tharimmune, Inc. Announces Closing of $11 Million Public Offering

Accesswire November 30, 2023

Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management

Newsfile November 30, 2023

Tharimmune, Inc. Announces Pricing of $10 Million Public Offering

Accesswire November 27, 2023
View More News ››

Opinion & Analysis (NDAQ:THAR)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:THAR)

RE:THAR.....NR this a.m

Sorry....never did update this. No position
Iseneschal - February 6, 2024

THAR.....NR this a.m

In some here at 46 cents
Iseneschal - February 5, 2024

THAR....she doesn't blow ; ) Now N.L.O.D

Buh Bye
Iseneschal - November 27, 2023

THAR ....P.O getting set up???

EDGAR Entity Landing Page (sec.gov)
Iseneschal - November 27, 2023

THAR.....I'll take my 10%...Thank you very much

Early a.m runner on NR
Iseneschal - November 27, 2023

THAR ...pop

greg
Iseneschal - September 26, 2023
View more Bullboard ››

Regenx Tech Corp.

Regenx Tech Corp.

Regenx Tech Corp. is a Canada-based company, which is engaged in development and commercialization of its environmentally ...
View More »